On August 31, Shenzhen Haplox Biotechnology Co., Ltd. (Haplox) and Shenzhen MGI Technology Co., Ltd. (MGI) officially announced their cooperation. Xu Mingyan, founder and CEO of Haplox, Yu Dejian, President of MGI, and other representatives attended the signing ceremony. According to the agreement, Haplox will build on the technical advantages of MGI’s DNBSEQ high-throughput sequencing platform and combine its own technologies in the fields of liquid biopsy to jointly promote the development of clinical application of tumor molecular diagnosis and help China’s precision diagnosis and treatment of tumors enter a new chapter.

Xu Mingyan (Left), founder and CEO of Haplox and Yu Dejian (Right), President of MGI on the signing ceremony

With the rapid development of high-throughput sequencing technology, the clinical application of tumor DNA sequencing has become more extensive in the field of tumor diagnosis and treatment. At the same time, the number of tested genes has gradually evolved from small panel (<50 genes) to large panel (hundreds or even thousands of genes), and even whole exome sequencing (WES). The purpose is to provide a more complete scientific basis and guidance for precision tumor diagnosis and treatment. Given these circumstances, ultra-high-throughput sequencers have become the best choice for companies that conduct tumor gene sequencing.

As one of the very first biological companies to carry out liquid biopsy in China, Haplox is well-known in the industry for ultra-micro tumor liquid biopsy. The company effectively guarantees the accuracy of detection through ultra-deep sequencing and provides reliable detection results for clinical patients. Notably, Haplox is also the first in the industry that provides raw data of the detection, establishing an accurate and reliable quality model with real data. With the arrival of MGI models such as DNBSEQ-T7, Haplox will create more possibilities and further promote high-quality development in the field of tumor diagnosis and treatment.

DNBSEQ-T7 officially delivered to Haplox!

MGISEQ-2000 officially delivered to Haplox!

Xu Mingyan, co-founder and CEO of Haplox, said, “Many years ago, when I was engaged in scientific research in the George Church Laboratory at Harvard University, I participated in the research and development of a number of high-throughput gene sequencers and had a good understanding of the world's leading gene sequencing technology. Therefore, I have high expectations for MGI’s DNBSEQ platform. After a series of comparative tests, we found that the performance of DNBSEQ platform developed by MGI is indeed excellent, especially DNBSEQ-T7, which has significant advantages in data output, sequencing time and cost. The most impressive thing is that MGI’s DNBSEQ platform has a low repetition rate and a high data utilization rate, which helps to greatly reduce sequencing cost. Based on the above experience, we will continue to uphold our value of patients first and carry out in-depth cooperation with MGI to make greater contributions to cancer treatment and detection in China.”

Duncan Yu, President of MGI, said, “High-quality core tools make up the foundation of life science research and clinical application. From MGISEQ-200/2000 to DNBSEQ-T7, MGI has gradually realized large-scale domestic production for a full range of high, medium and low throughput sequencers, with applications serving the upstream and downstream in the industry. The cooperation with Haplox will promote the application of tumor molecular diagnosis based on the technical advantages of the DNBSEQ platform and unlock more possibilities. ”

Group photo of Haplox and MGI 

About DNBSEQ-T7

As the highest throughput sequencer to date, DNBSEQ-T7 has been certified by the China National Medical Product Administration (NMPA) and CE-IVD. DNBSEQ-T7 has achieved several breakthroughs – the maximum number of effective reads can reach 5000M, the effective data output of PE150 sequencing can achieve up to 1.5Tb, and a 4-chip sequencing platform can generate 6Tb of data per day. With ultra-high throughput, the sequencing speed of DNBSEQ-T7 is also excellent. It can complete SE50 sequencing within 5~6 hours, PE100 within 20~22 hours and PE150 within 24 hours.

About MGISEQ-2000

As a multi-functional desktop sequencer, MGISEQ-2000 can realize six different reading lengths (SE50, SE100, PE100, PE150, PE200 and SE400) and has been widely used in the field of tumor gene detection. MGISEQ-2000 also has features such as flexible data output. It can adapt to two types of slides (FCL/FCS), carry 1-2 slides in a single run, and provide five different slide combination modes. The operation data output can cover from 55G to 1440G, and it only takes 13 hours to complete SE100 sequencing at full capacity.